B. Riley Financial Varied
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

3.800 +0.010 (+0.26%)
Streaming Delayed Price Updated: 10:04 AM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 211,745
Open 3.870
Bid (Size) 3.800 (5)
Ask (Size) 3.810 (4)
Prev. Close 3.790
Today's Range 3.794 - 3.870
52wk Range 1.195 - 4.430
Shares Outstanding 36,213,654
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Black Diamond (BDTX) Q2 Loss Narrows 47%
Via The Motley Fool
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire

Performance

YTD
+77.6%
+77.6%
1 Month
+35.7%
+35.7%
3 Month
+53.2%
+53.2%
6 Month
+155.0%
+155.0%
1 Year
-12.6%
-12.6%

More News

Read More
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
These stocks have an unusual volume in today's session
Via Chartmill
Unusual volume stocks in Thursday's session
Via Chartmill
These stocks are the most active in today's session
Via Chartmill
What's going on in today's session
Via Chartmill
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Wednesday's session: gap up and gap down stocks
Via Chartmill
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million
Via Benzinga
Discover the top movers in Wednesday's pre-market session.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements
Via AB Newswire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Via Benzinga
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
From Black Diamond Therapeutics, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Black Diamond Therapeutics, Inc. - Common Stock publicly traded?
Yes, Black Diamond Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Black Diamond Therapeutics, Inc. - Common Stock trade on?
Black Diamond Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock?
The ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock is BDTX on the Nasdaq Stock Market
What is the current price of Black Diamond Therapeutics, Inc. - Common Stock?
The current price of Black Diamond Therapeutics, Inc. - Common Stock is 3.800
When was Black Diamond Therapeutics, Inc. - Common Stock last traded?
The last trade of Black Diamond Therapeutics, Inc. - Common Stock was at 10/01/25 10:04 AM ET
What is the market capitalization of Black Diamond Therapeutics, Inc. - Common Stock?
The market capitalization of Black Diamond Therapeutics, Inc. - Common Stock is 137.61M
How many shares of Black Diamond Therapeutics, Inc. - Common Stock are outstanding?
Black Diamond Therapeutics, Inc. - Common Stock has 138M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.